Oblato, Inc.
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma (NCT05561374) | Oblato, Inc. | 2023-04-17 |
| Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants (NCT03649464) | Oblato, Inc. | 2022-08-01 |
| Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma (NCT04388475) | Oblato, Inc. | 2020-06-12 |
Track Oblato, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.